IMPORTANCE Dual anti-HER2 blockade increased the rate of pathologic complete response (pCR) in the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial, and high immune gene expression was associated with pCR in all treatment arms. So far, no marker has been identified that is specifically associated with the benefit from dual HER2 blockade.
T he Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial demonstrated that trastuzumab, a monoclonal antibody against HER2, and lapatinib, a small-molecule tyrosine kinase inhibitor of the EGFR and HER2 family, administered together with paclitaxel chemotherapy in the neoadjuvant setting increased rates of pathologic complete response (pCR) by approximately 20% in patients with early-stage HER2-positive breast cancer compared with either treatment alone. 1 A higher tumorassociated lymphocyte count 2 and a higher expression of immune signatures 3 were associated with higher rates of pCR but not with specific benefit from dual treatments. In this study, we examine whether specific T-cell receptor (TCR) species could indicate an association with response to a specific treatment arm. The TCR recognizes peptide antigens bound to major histocompatibility complex molecules and is composed of 2 different protein chains, α and β ( Figure 1A) . Each TCR possesses unique antigen specificity determined by the structure of the antigen-binding site formed by the α and β chains. T-cell receptor diversity arises from the random combinatorial joining of variable, joining, and diversity genes to generate each complete chain that defines antigen specificity. We estimate the diversity of T-cell populations in the tumor microenvironment by assessing the messenger RNA expression of the T-cell receptor β chain variable (TRBV) gene from previously published RNA sequencing data 3 of pretreatment biopsies of patients in the NeoALTTO trial.
Methods
A total of 455 patients with HER2-positive early-stage breast cancer were randomized to 3 treatment arms in the NeoALTTO trial. 1 Baseline biopsies were performed on 423 of these patients, and RNA was successfully extracted from 254 patients, of which 245 had matching clinical data (eFigure 1 in the Supplement).
Key Points
Question Does the use of specific T-cell receptor β variable region (TRBV) genes add to the association of immune markers with anti-HER2 therapy in HER2-positive breast cancer?
Findings In this biomarker study of data from the NeoALTTO trial, high levels of a TRBV metagene consisting of 3 individual TRBV genes identified a subgroup of patients who respond poorly to single HER2 blockade treatments, irrespective of overall immune signature expression, but who experience a significant benefit from dual anti-HER2 blockade.
Meaning Direct measurements of TRBV use is an independent biomarker for response to dual HER2-targeted therapy. Data for multivariable analysis were available for 225 patients (eTable1intheSupplement). We adapted a previously published method 4 to map aligned reads from bulk RNA sequencing data against a database of human TCR genes to identify use of variable region TCR sequences (the software is available at https: //github.com/ElementoLab/TCRVseq). The total TRBV load, TRBV richness, and TRBV entropy were used to characterize TRBV use in tumors and to identify co-use of TRBV metagenes using nonnegative matrix factorization (eAppendix 1 in the Supplement).
Features of TRBV use were evaluated for association with pCR using multivariable logistic regression adjusted for clinical covariates (eAppendix 2 in the Supplement). This biomarker study was approved by the Human Investigations Committee of Yale Cancer Center. Written informed consent was obtained from all patients at entry into the NeoALTTO trial, which also covered future biomarker research.
Results

Characterization of TRBV Variant Use
The read length of standard RNA sequencing does not allow reconstructing the entire T-cell β chain; for this reason, we refer to use of a specific TRBV gene in TCRs in a tumor instead of TCR gene expression. Hierarchical clustering with bootstrap resampling identified a stable cluster of tumors that showed minimal use of most TRBV genes ( Figure 1B . The overall TRBV load was highly correlated with tumor-associated lymphocyte counts (eFigure 3 in the Supplement) and was significantly higher in patients who achieved a pCR (P = .009 determined by use of the Wilcoxon rank-sum test). We found the use of different TRBV genes to be highly correlated (median pairwise Pearson correlation, 0.43 [range, -0.09 to 0.82]) (eFigure 4 in the Supplement) and used nonnegative matrix factorization to define 4 metagenes (TMG1-TMG4) that captured the broader TRBV use patterns across tumors (eFigures 5 and 6 in the Supplement). Each metagene contained at most 1 gene from each TRBV subgroup (eFigure 7 and eTable 2 in the Supplement), implying less than 75% sequence identity between genes of a given metagene. All 4 metagenes representing median use of the TRBV genes were significantly higher in patients with pCR (eFigure 8 in the Supplement).
Metrics for TRBV were generally correlated with other measures of immune activity but not with the rate of somatic mutation or proliferation metagene expression (eFigures 3 and 9 in the Supplement). Tumor-associated lymphocyte counts were available for 225 tumor samples in the cohort 2 and found to be positively correlated with a previously reported immune signature (ρ = 0.43; P < .001), TRBV load (ρ = 0.37; P < .001), and the levels of all 4 TMGs (TMG1, ρ = 0.22; TMG2, ρ = 0.28; TMG3, ρ = 0.39; and TMG4, ρ = 0.34).
We assessed whether the global TRBV metrics, individual TRBV gene use, and TMGs, are associated with pCR in estrogen receptor-adjusted logistic regression. Only TRBV11-3 use (odds ratio, 1.67 [95% CI, 1.26-2.27]; adjusted P = .04) and meta- gene TMG2 (odds ratio, 1.49 [95% CI, 1.14-1.96]; adjusted P =.04) were significantly associated with pCR in the overall cohort (eTable 3 in the Supplement). In multivariable logistic regression that included clinical variables and known prognostic signatures (eAppendix 2 in the Supplement), TMG2 and TRBV11-3 had statistically significant treatment-arm interaction terms, indicating that higher use is associated with greater probability of pCR in patients treated with dual HER2 blockade compared with patients in the single treatment arms (Table) . When both TMG2 and TRBV11-3 were considered together, only the TMG2 interaction term for combined therapy vs single treatments remained significant (interaction odds ratio, 5.03 [95% CI, 1.62-18.46]; P = .009) (Table) .
To examine the added information on association with pCR provided by TMG2, patients were dichotomized (median split) by TMG2 level and by immune signature expression into high and low groups. Patients with high TMG2 levels and immune-rich tumors (92 of 245 [37.6%]) had a significantly higher pCR rate in the dual HER2-targeted arm compared with the other arms (68% [95% CI, 52%-83%] vs 21% [95% CI, 10%-31%]; P < .001 determined by use of the Fisher exact test) ( Figure 2) . A high TMG2 level was also associated with a higher rate of pCR to combined therapy in immune-poor tumors (30 of 245 [12.2%]), where the rate of pCR was 6% (95% CI, 0%-16%) with monotherapy vs 50% (95% CI, 22%-78%) with dual HER2 blockade (P = .009 determined by use of the Fisher exact test). The interaction of TMG2 by treatment was also significant for the lapatinib vs combined therapy but not for trastuzumab vs combined therapy (eTables 4 and 5 in the Supplement) in 2-marker models, suggesting that the T-cell metagene may be associated with a specific trastuzumab benefit in the context of comparison with combined therapy. High use of the single variable-gene TRBV11-3, which is not included in any of the 4 TMGs, showed the same characteristics as TMG2 in immune-rich and immune-poor cancers (eFigure 10 in the Supplement).
Discussion
Our analysis indicates that use of a very small number of TRBV genes (TRBV4.3, TRBV6.3, TRBV7.2, and TRBV11.3) appears to be associated with selective response to dual treatment with trastuzumab and lapatinib, both in immune-rich and immunepoor cancers. The small number of TRBV genes involved suggests the possibility that only a small number of genes, and possibly a small number of TCRs, are needed to estimate the immunogenic activity associated with trastuzumab response and subsequent sensitivity to dual HER2 blockade, even when overall immune infiltration is modest. These TRBV genes have very high use in normal CD4-positive follicular helper T cells 5 that have been associated with better outcomes after therapy, 6 which may suggest as a possible mechanism that previous infections in some patients could prime the T FH effector cells for responses that augment the outcome of HER2-targeted therapy regimens. 7 
Limitations
One limitation of our study is that, owing to the insert size of the RNA sequencing complementary DNA library and the limits on read length in current sequencing technology, we were unable to fully reconstruct the T-cell β chain to identify specific rearranged TCRs from bulk RNA sequencing data. Moreover, these findings are exploratory and will need to be confirmed in additional cohorts, and potentially with dual regimens combining trastuzumab with pertuzumab. Finally, this study was not designed to assess whether the pCR benefit translates to better survival outcomes in these patients.
Conclusions
Use of a small number of TRBV genes potentially provides information about the association with response to dual HER2 blockade beyond immune gene signatures. If confirmed in additional cohorts, the TRBV signature could help identify patients who do poorly with single anti-HER2 treatments, but benefit from dual blockade. 
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RNA sequencing
From 254 RNA samples, Illumina paired-end sequencing libraries were successfully constructed and subjected to sequencing on the Illumina HiSeq 2500 system as described previously 1 . Read pairs were trimmed using Trimmomatic 2 , alignment was performed using STAR 3 . Immune, proliferation and treatment response metagene scores, calculated as the weighted sum of the log-FPKM expression of their member genes, were taken from the original publication 1 .
In this analysis, we focus on the usage of TRBV genes due to their increased sequence diversity compared to alpha chain variable genes. We defined the following TRBV population-wide metrics:
(i) Total TRBV Load was calculated as the sum of all reads aligning to any TRBV variant in a sample.
(ii) TRBV richness was calculated as the number of distinct TRBV-genes per sample whose usage was non-zero. (iii) TRBV entropy was calculated as the Shannon diversity index of TRBV usage normalized by the natural logarithm of TRBV richness. All post-processing and statistical analysis was conducted in R 4 .
Hierarchical clustering of TRBV usage
The Euclidean distance matrix was calculated from the natural log of TRBV CPMs across patients. To stabilize numerical computations, a pseudo-count of 1 was added to each count value before taking the logarithm. Samples were clustered using average linkage, and the stability of the cluster was evaluated using the approximately unbiased p-value from multiscale bootstrap resampling using the pvclust package 5 .
Non-negative matrix factorization:
Non-negative matrix factorization (NMF) was performed using 150 runs of the Brunet et al. algorithm from the nmf package 6, 7 . A factorization rank of 4 was chosen based on 50 runs for ranks 2 through 6. The highest rank at which the cophenetic coefficient decreased was chosen, as suggested in the original manuscript by Brunet et al. Individual TRBV genes from NMF were selected as significant contributors to a TRBV metagene using the feature selection method described in Carmona-Saez et al. 8 . The method considers TRBV genes by their contributing weights to each factor, and for each factor selects a sparse set of TRBV genes that contribute uniquely to that factor and no others. The median usage of these factor-specific TRBV genes were used to define the four T-cell receptor metagenes (TMG).
Logistic regression
Population-wide TRBV metrics and NMF-derived TMGs were considered in covariate-adjusted logistic regression to predict pCR. In ER-adjusted analyses, we corrected for estrogen receptor (ER) status and tested nested models with and without each TRBV metric using the Wald approximation of the likelihood ratio test. We corrected for multiple testing using the Holm step-down procedure 9 . In multivariable models, we adjusted for age (continuous), tumor size (>=T3 vs. T2), grade (1-2 vs. 3), estrogen receptor status (negative vs. positive) and node status (N0/N1 vs. N2-N3), TIL counts, immune gene signature (Immune3), a proliferation signature (GGI), a stromal signature (Stroma1) and treatment arm in the 225 patients for which all data was available. Gene expression signatures were selected by their significance in the analysis conducted by Fumagelli et al. 1 Based on high correlation between gene expression signatures for similar phenotypes, only one immune signature and one stromal signature was chosen. All covariates were standardized. Each TRBV feature was included as a base term and as an interaction term with the treatment arm. Terms were tested for significance in their respective models using the Wald approximation of the likelihood ratio test. The significance of TCR effect overall in each model was tested using a chi-squared test of the likelihood ratio of nested models with or without TCR terms with 2 or 4 degrees of freedom depending on the number of TCR terms in the model.
eAppendix 2. Statistical Analysis Logs
> load("NeoALTTOData.RData") > regressionvariables = c("Entropy", "Variety", "TTL", "TMG1", "TMG2", "TMG3", "TMG4", "TIL", "TRBV11.3", "Immune3") > pvalueAll = NULL > for (v in c(regressionvariables)) { + print(paste(v, " ER adjusted model", sep="")) + logReg = glm(as.formula(paste("factor(pCR4FL) ~ ERCat + ", v)), data = immuneData, family = binomial) + print("ORs") + print(exp(coef(logReg))) + print("95% CIs") + print(exp(confint(logReg))) + print("P values") + pv = coef(summary(logReg) 
